Get the Stockscreener App
0.744
0.80%
-0.006
Iterum Therapeutics Plc stock is traded at $0.744, with a volume of 615.64K.
It is down -0.80% in the last 24 hours and down -10.36% over the past month.
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
See More
Previous Close:
$0.75
Open:
$0.7446
24h Volume:
615.64K
Relative Volume:
0.86
Market Cap:
$33.22M
Revenue:
-
Net Income/Loss:
$-35.58M
P/E Ratio:
-0.2808
EPS:
-2.65
Net Cash Flow:
$-42.82M
1W Performance:
-13.80%
1M Performance:
-10.36%
6M Performance:
-50.07%
1Y Performance:
-38.51%
1-Day Range:
$0.7303
$0.7845
1-Week Range:
$0.71
$0.9073
52-Week Range:
$0.6573
$3.02
Iterum Therapeutics Plc Stock (ITRM) Company Profile
Name
Iterum Therapeutics Plc
Sector
Industry
Phone
(872) 225-6077
Address
3 DUBLIN LANDINGS, DUBLIN 1
Compare ITRM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ITRM
Iterum Therapeutics Plc
|
0.744 | 38.85M | 0 | -35.58M | -42.82M | -2.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Iterum Therapeutics Plc Stock (ITRM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-28-21 | Upgrade | Gabelli & Co | Sell → Hold |
| Mar-15-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jun-02-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-21-20 | Downgrade | Gabelli & Co | Buy → Sell |
| Dec-11-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-21-19 | Initiated | H.C. Wainwright | Buy |
View All
Iterum Therapeutics Plc Stock (ITRM) Latest News
Iterum Therapeutics plc (NASDAQ:ITRM) Q2 2025 Earnings Call Transcript - MSN
Fibonacci Support Holding Strong in Iterum Therapeutics plcJuly 2025 Macro Moves & High Accuracy Buy Signal Tips - newsyoung.net
ITRM Reports Results - AOL.com
Iterum launches first oral penem antibiotic for urinary tract infections - Investing.com
Iterum Therapeutics Launches New Antibiotic ORLYNVAH - TipRanks
Iterum Therapeutics Launches ORLYNVAH™: First Oral Penem Antibiotic Approved for Uncomplicated UTIs in Over 25 Years - Quiver Quantitative
Iterum Therapeutics launches ORLYNVAH™, the first and only oral penem antibiotic in the U.S. - MarketScreener
First-Ever Oral Penem Antibiotic: Iterum's ORLYNVAH Launches to Combat Drug-Resistant UTIs in Women - Stock Titan
How to manage a losing position in Iterum Therapeutics plcJuly 2025 Sentiment & Community Verified Trade Alerts - Newser
Should you wait for a breakout in Iterum Therapeutics plc2025 Geopolitical Influence & Community Consensus Trade Signals - Newser
Order Flow Trends Show Accumulation in Iterum Therapeutics plcGap Up & Real-Time Buy Signal Notifications - beatles.ru
Technical analysis overview for Iterum Therapeutics plc stockBreakout Watch & Risk Controlled Swing Trade Alerts - Newser
What institutional flow reveals about Iterum Therapeutics plcJuly 2025 Price Swings & Capital Efficient Trade Techniques - Newser
Live market analysis of Iterum Therapeutics plcJuly 2025 Selloffs & Detailed Earnings Play Strategies - Newser
Using data filters to optimize entry into Iterum Therapeutics plcJuly 2025 Recap & Fast Gain Swing Alerts - Newser
Exit strategy if you’re trapped in Iterum Therapeutics plcWeekly Loss Report & Low Drawdown Investment Ideas - Newser
Will Iterum Therapeutics plc continue its uptrend2025 Momentum Check & AI Enhanced Execution Alerts - Newser
Price momentum metrics for Iterum Therapeutics plc explainedMarket Growth Review & Weekly Return Optimization Alerts - Newser
Iterum Therapeutics plc Facing Inflection Point in Trend Analysis2025 Macro Impact & Reliable Price Action Trade Plans - 선데이타임즈
What’s next for Iterum Therapeutics plc stock priceJuly 2025 Weekly Recap & Technical Analysis for Trade Confirmation - Newser
Using economic indicators to assess Iterum Therapeutics plc potentialMarket Growth Summary & Free Weekly Chart Analysis and Trade Guides - Newser
Chart based exit strategy for Iterum Therapeutics plcEarnings Overview Report & Daily Stock Trend Reports - Newser
Is Iterum Therapeutics plc reversing from oversold territory2025 Dividend Review & Community Supported Trade Ideas - Newser
What are Iterum Therapeutics plc’s earnings expectationsTrade Entry Summary & Safe Capital Growth Trade Ideas - thegnnews.com
Intraday pattern recognizer results for Iterum Therapeutics plcBreakout Watch & Real-Time Volume Analysis Alerts - Newser
Iterum Therapeutics plc’s Price Action Aligns with Quant SignalsJuly 2025 Final Week & Risk Controlled Stock Pick Alerts - metal.it
Advanced analytics toolkit walkthrough for Iterum Therapeutics plcMarket Sentiment Summary & Breakout Confirmation Trade Signals - Newser
News impact scoring models applied to Iterum Therapeutics plcDay Trade & Technical Pattern Based Signals - Newser
Analyzing Iterum Therapeutics plc with multi timeframe charts2025 Price Targets & Entry Point Confirmation Alerts - Newser
Leading vs lagging indicators on Iterum Therapeutics plc performance2025 Fundamental Recap & Capital Protection Trading Alerts - Newser
Iterum Therapeutics plc stock trend outlook and recovery path2025 Year in Review & Weekly Top Gainers Alerts - Newser
Using Bollinger Bands to evaluate Iterum Therapeutics plc2025 Retail Activity & Technical Buy Zone Confirmations - Newser
Iterum Therapeutics plc Reaches Critical Trendline SupportWeekly Gains Report & Comprehensive Market Scan Insights - newsyoung.net
Using Ichimoku Cloud for Iterum Therapeutics plc technicalsTrade Volume Report & Scalable Portfolio Growth Methods - Newser
Iterum therapeutics (ITRM) director Dunne buys $10,854 in shares - Investing.com
Iterum therapeutics (ITRM) director Dunne buys $10,854 in shares By Investing.com - Investing.com Australia
Iterum Therapeutics Director Dunne Buys 15,000 Shares at $0.72/Share on Aug 8. - AInvest
Real time pattern detection on Iterum Therapeutics plc stockSecure Buy Strategy Based on Risk Parameters - Newser
Why Iterum Therapeutics plc stock attracts strong analyst attentionLow Drawdown Picks with Weekly Updates - Newser
Developing predictive dashboards with Iterum Therapeutics plc dataFuture Growth Stock Forecasting Strategy - Newser
Will Iterum Therapeutics plc stock recover after recent dropReal Stock Picks With Setup Verification - Newser
Iterum Therapeutics Plc Stock (ITRM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):